Figure 1
From: Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
Cytoplasmic RAP1 is an indicator of high-grade NSCLC. (a and b) Expression of cytoplasmic and nuclear RAP1 in lung adenocarcinoma (a) and squamous cell carcinoma (b) tissues, as well as peri-tumoral normal tissues (PTNT). (c and d) Expression of cytoplasmic RAP1 in Grade I–III adenocarcinoma (c) and squamous cell carcinoma (d) tissues. (e) Kaplan–Meier analysis and Log-rank (Mantel–Cox) test of the survival between RAP1-high (n=33, expression >0.4) and RAP1-low (n=59, expression <0.4) adenocarcinoma patients. (f) Representative images of RAP1 expression in adenocarcinoma, squamous cell carcinoma and PTNT, arrowhead: cytoplasmic RAP1; scale bar: 10 μm. *P<0.05, **P<0.01, ***P<0.001, Student’s t-test
